For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Famotidine 20 mg FCT With Water | Famotidine 20 mg FCT (film-coated tablet) with 120 mL of water | None | None | 0 | 30 | 4 | 30 | View |
| Famotidine 20 mg CT Without Water | Famotidine 20 mg Chewable Tablet without water | None | None | 0 | 30 | 3 | 30 | View |
| Famotidine 20 mg CT With Water | Famotidine 20 mg chewable tablet with 120 mL of water | None | None | 0 | 30 | 4 | 30 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Dizziness | SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDRA 9.0 | View |
| Headache | SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDRA 9.0 | View |
| Rhinitis | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDRA 9.0 | View |
| Syncope vasovagal | SYSTEMATIC_ASSESSMENT | Vascular disorders | MedDRA 9.0 | View |